Prevalence of chronic hepatitis B and C in psoriasis patients: A cross-sectional study in a large US population

Orrell, Kelsey A.; Vakharia, Paras P.; Hagstrom, Erika L.; Brieva, Joaquin C.; West, Dennis P.; Nardone, Beatrice

doi:10.1016/j.jaad.2017.05.020

Cited by 12 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIV has been shown to be an independent risk factor for the development of psoriasis . Previous studies found conflicting results of whether hepatitis B or C are associated with higher rates of psoriasis . However, chronic infections such as HIV and hepatitis may increase risk for HS owing to immune dysregulation, shared lifestyle factors and/or health behaviours.…”

Section: Discussionmentioning

confidence: 99%

“…26 Previous studies found conflicting results of whether hepatitis B or C are associated with higher rates of psoriasis. [27][28][29][30][31] However, chronic infections such as HIV and hepatitis may increase risk for HS owing to immune dysregulation, shared lifestyle factors and/or health behaviours. Future studies are needed to confirm these associations and determine the precise mechanism(s) of association between HS and serious infections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults

et al. 2019

View full text Add to dashboard Cite

Summary Background Hidradenitis suppurativa (HS) is associated with bacterial colonization, skin‐barrier disruption, immune dysregulation and treatments that can increase infection risk. Objectives To determine whether HS is associated with cutaneous and extracutaneous infections and related outcomes. Methods Data from the 2002–2012 National Inpatient Sample were analysed, including a 20% sample of U.S. hospitalizations (n = 87 053 155). Results The prevalence (with 95% confidence interval) of infections was higher in adults (34·0%, 33·2–34·7% vs. 23·4%, 23·2–23·6%) and children (31·8%, 28·7–34·9% vs. 12·6% (12·1–13·1%) with vs. without HS. Inpatients with HS had higher prevalences of infections overall (excluding cellulitis and erysipelas) than those with psoriasis, but lower than those with atopic dermatitis. In multivariable logistic regression models adjusting for sociodemographics, HS was associated with 18 of 45 infections examined (adults: 16 of 45; children: six of 45), including acute infections (herpes simplex virus, herpes zoster, necrotizing fasciitis, septicaemia, bone infection, Clostridium difficile, methicillin‐sensitive and methicillin‐resistant Staphylococcus aureus, Streptococcus, Pseudomonas, mycobacterial, fungal, viral), chronic infections (HIV, hepatitis B) and antibiotic‐resistant infections. HS alone was associated with increased infections. Patients with comorbid cancer; HIV; cardiometabolic, autoimmune or mental health diagnoses or acne had even higher odds of infections. Inpatients with HS with vs. without serious infection had increased inpatient mortality (0·71% vs. 0·16%), mean length of stay (7·3 vs. 4·8 days) and cost of care (US$13 578 vs. $9242), with a mean annual excess 41 050 days and $71 622 339 cost of hospitalization. Conclusions Adults and children with HS had increased acute and chronic, cutaneous, extracutaneous and systemic infections, which were associated with increased mortality and cost. What's already known about this topic? Little is known about the risk of infection in patients with hidradenitis suppurativa (HS). What does this study add? Adults and children with HS had increased cutaneous, extracutaneous and systemic infections, at even higher rates than in patients with psoriasis and atopic dermatitis. These infections were associated with increased inpatient mortality and cost. Respond to this article

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults

et al. 2019

View full text Add to dashboard Cite

show abstract

“…11 studies (8 cross-sectional and 3 case-control) examined the association of hepatitis C in psoriasis patients, as shown in Table 1. Risk of bias assessment revealed nine studies of higher quality [23][24][25][27][28][29][30][31][32] and two studies of lower quality, as shown in Fig. 2A [22,26].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…A total of 11 studies, including 3 case control and 8 cross-sectional studies with 25,047 psoriasis patients and 4,091,631 controls provided data for this outcome [22][23][24][25][26][27][28][29][30][31][32]. We identi ed substantial statistical heterogeneity across these 11 studies (I 2 = 89%).…”

Section: Association Of Psoriasis With Hepatitis C In Studiesmentioning

confidence: 99%

Is There a Relationship Between Psoriasis and Hepatitis C?: a Meta-analysis and Bioinformatics Investigation

Liu

Cui

Duan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The relationship between psoriasis and hepatitis C was previously controversial, so our purpose is to investigate this connection.Methods: We conducted a systematic review of the case-control, cross-sectional and cohort studies examining the association between psoriasis and hepatitis C in PubMed, EMBASE and Cochrane library databases and investigated the overlapping genes between psoriasis targets and hepatitis C targets using bioinformatics analysis. Based on overlapping genes and hub nodes, we also constructed the protein-protein interaction (PPI) network and module respectively, followed by the pathway enrichment analysis. Results: We included 11 publications that reported a total of 11 studies (8 cross-sectional and 3 case-control). The case–control and cross-sectional studies included 25,047 psoriasis patients and 4,091,631 controls in total. Psoriasis was associated with a significant increase of prevalent hepatitis C (OR 1.72; 95% confidence interval [CI] (1.17-2.52)). A total of 389 significant genes were common to both hepatitis C and psoriasis, which mainly involved IL6, TNF, IL10, ALB, STAT3 and CXCL8. The module and pathway enrichment analyses showed that the common genes had the potential to influence varieties of biological pathways, including the inflammatory response, cytokine activity, cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, which play an important role in the pathogenesis of hepatitis C and psoriasis.Conclusion: Patients with psoriasis display increased prevalence of hepatitis C and the basic related mechanisms between hepatitis C and psoriasis had been preliminarily clarified.

show abstract

“…By using RADAR (Research on Adverse Drug events And Reports), 3 a previously described medical record data repository, the Northwestern Medicine Enterprise Data Warehouse (NMEDW, [5 million patients) 3 provided data for patients exposed to secukinumab (Jan 2015-Aug 2017) or ixekizumab (Jan 2016-Aug 2017) who had a subsequent first diagnosis of CD (International Classification of Diseases, Ninth Revision, [ICD-9] code 555.9 or Tenth Revision [ICD-10] code K50.90) or UC (ICD-9 code 556, ICD-10 K51).…”

mentioning

confidence: 99%

Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program

Orrell

Murphrey

Kelm

et al. 2018

Journal of the American Academy of Dermatology

Self Cite

View full text Add to dashboard Cite

Prevalence of chronic hepatitis B and C in psoriasis patients: A cross-sectional study in a large US population

Cited by 12 publications

References 4 publications

Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults

Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults

Is There a Relationship Between Psoriasis and Hepatitis C?: a Meta-analysis and Bioinformatics Investigation

Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program

Contact Info

Product

Resources

About